@SJCapitalInvest Congrats and best wishes on your next chapter!! And super thankful for your sharing in this community. Do you have LinkedIn account we can follow you?
Why is our FDA slow walking #ANKTIVA and NK Cell therapy when now, foreign Governments are approving it and saving lives?
Saudi Arabia, The UK and now ASIA!!!
@POTUS you signed right to try in 2018 and the @FDA is letting foreign Nations lead with US technology to treat Cancer.
My brain is exploding!
@bullishbruk@pdsandiego
Don Lemon didn’t just show up and report what happened. He knew what was going to happen, knew it was supposed to be secret, and helped keep it secret.
You don’t get to invade people’s private space and interrupt a religious service in the name of “free speech.”
Calling it “journalism” doesn’t turn participation into reporting.
That’s why he’s facing federal felony charges. He participated in interrupting people’s constitutionally protected rights.
🚨WHY LEMON WAS CHARGED
Can we please stop lying around here? Here's the grand jury indictment laying out why Don Lemon was charged.
At the pre-op briefing Chauntyll Louisa Allen briefed Lemon and the other conspirators about where and what they were doing.
On camera, Nekima Armstrong tells Lemon—who knows the location but is hiding it from his audience—that they're going to "disrupt business as usual" at what we later learned was Cities Church.
Lemon said he would see her there.
https://t.co/s3JEj8S2WZ
🧵1/7
The FDA needs to get ANKTIVA and the NK cell infusion process into every hospital. Dr. Pat cannot treat 15,000 patients in a single clinic. This must be approved for all cancer patients, not a slow, one-at-a-time model. Patients deserve the Right to Try. Cut the red tape. Unleash #ANKTIVA.
@RobertKennedyJr
@DrMakaryFDA
An incredibly inspiring conference between scientists, patients, and our governments... to address the health challenges of our times. The conference recordings will be released daily this coming week @latimesstudios_ and I will provide context daily till its all released on each segment
https://t.co/VeHGIo5mOf
71% complete response rate with Anktiva in bladder patients who FAILED BCG with both CIS & Papillary. Waiting for final approval from EMA
With this result in BCG unresponsive disease, can’t wait to see what the CR rate is in BCG naive patients who are responsive to BCG + Anktiva. Complete enrollment soon
https://t.co/LYZbQsJ7TA
1/ 🚨 Debunking the $TE Short Report: Today @CulperResearch dropped a "short" on T1 Energy, alleging it's a "China Proxy" destined for zero. But the data tells a different story. Let’s look at the facts Culper ignored or misrepresented.